What is Delfi Diagnostics?
DELFI Diagnostics is at the forefront of early cancer detection, leveraging its proprietary Fragmentomics Platform. This advanced technology employs sophisticated machine learning algorithms and next-generation sequencing to analyze cell-free DNA extracted from liquid biopsy samples. Their product suite, including FirstLookLung for healthcare providers and patients, and DELFI-TF for treatment monitoring, aims to revolutionize cancer care. By offering scalable and effective screening solutions, DELFI Diagnostics serves healthcare systems, pharmaceutical partners, and patients, driven by a leadership team with deep expertise in genomics, AI, and cancer biology. The company's mission is to transform cancer care and significantly improve patient outcomes.
How much funding has Delfi Diagnostics raised?
Delfi Diagnostics has raised a total of $325M across 2 funding rounds:
Series A
$100M
Series B
$225M
Series A (2021): $100M with participation from OrbiMed Advisors LLC, AV8 Ventures, Windham Venture Partners, Menlo Ventures, Samsara Biocapital, and Illumina Ventures
Series B (2022): $225M led by Brown Advisory, Point72, DFJ Growth, and Eli Lilly and Company Pvt
Key Investors in Delfi Diagnostics
Point72
Point72 is a private investment management firm established in 1992, managing various private investment funds. They are headquartered in Stamford, Connecticut.
DFJ Growth
DFJ Growth is a late-stage global venture capital firm founded in 2005, providing capital to companies in seed, early, and growth stages, with a focus on rapidly scaling technology companies poised for market leadership. They are headquartered in California.
Eli Lilly and Company Pvt
Eli Lilly and Company Pvt, a subsidiary of the global biopharmaceutical company, specializes in developing advanced treatment options for chronic diseases and focuses on medical and health innovations. They operate in India and the Asia-Pacific region.
What's next for Delfi Diagnostics?
With substantial enterprise-level backing, Delfi Diagnostics is strategically positioned for accelerated growth and market expansion. The recent major strategic investment signals strong confidence from its backers, likely enabling the company to further refine its Fragmentomics Platform, scale its commercial operations, and broaden the reach of its early cancer detection solutions. This infusion of capital is expected to fuel continued innovation in liquid biopsy technology and solidify Delfi's leadership in the competitive oncology diagnostics landscape, potentially leading to new product development and strategic partnerships.
See full Delfi Diagnostics company page
